This episode’s Community Champion Sponsor is Catalyst. To virtually tour Catalyst and claim your space on campus, or host an upcoming event: CLICK HERE
During this episode, Dr. David Klimstra, Founder and Chief Medical Officer at Paige, joins us to discuss how his company is driving a new era of diagnostics and precision treatment to improve the lives of cancer patients.
While together, Dr. Klimstra shares how Paige has created decision-support diagnostic tools and a cloud-based platform for pathologists, enabling them to review digital slides and perform AI tasks on tissue samples.
Additionally, Dr. Klimstra emphasizes the importance of prioritizing patient care in developing and using AI technologies and advises healthcare transformers to be patient and persistent in their pursuit of transforming healthcare.
Join us for this timely and important conversation and to learn how Dr. Klimstra and the Paige team are transforming cancer diagnosis and treatment with artificial intelligence. Let’s go!
- How Paige uses AI assistance in cancer diagnosis and treatment
- How Paige creates decisions that support diagnostic tools and a platform for pathologists
- Digital biomarkers for the prediction of mutations, survival, and recurrence/response to treatment
- How Paige received Breakthrough Status from FDA for prostate biopsy model
- Importance of patient care in the development and use of AI technologies
- Advice for healthcare transformers to be patient and persistent
About our Guest:
David Klimstra, M.D. is Founder and Chief Medical Officer at Paige, the first company to receive FDA approval for an AI product in digital pathology, Paige Prostate. He also serves as Medical Consultant at Memorial Sloan Kettering Cancer Center and Professor of Pathology and Laboratory Medicine at Weill Medical College of Cornell University. An internationally recognized expert on the pathology of tumors of the digestive system, pancreas, liver, and neuroendocrine system, he has published over 425 primary articles and his research focuses on the correlation of morphological and immunohistochemical features of tumors of the gastrointestinal tract, liver, biliary tree, and (most notably) pancreas with their clinical and molecular characteristics. Dr. Klimstra received his M.D. and completed a residency in anatomic pathology at Yale University, and he completed fellowship training in oncologic surgical pathology at Memorial Sloan Kettering Cancer Center.
Links Supporting This Episode: